How India’s Torrent Is Building Resilience In Brazil
This article was originally published in PharmAsia News
Executive Summary
India’s Torrent Pharmaceuticals reported a strong set of numbers for the third quarter ended December 2015 despite turbulence in markets like Brazil, where it has done some sharp "belt tightening" but remains bullish over the long term.
You may also be interested in...
Can A Transformed ANVISA Sustain Torrent's Brazilian Mojo?
Price gains and a regulator that has turned more responsive appear to be among the key factors contributing to the improving sentiment in Brazil for India's Torrent even as the South American nation tackles intense political and economic turbulence. While Torrent reported a sharp decline in its earnings in the first quarter largely due to exceptional gains in the comparable previous period, its Brazilian business is looking up.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet